Tata 1mg hits EBITDA positive in FY26; diagnostics ARR crosses Rs 600 crore
Tata 1mg turned EBITDA positive across core businesses in FY26 as diagnostics ARR crossed Rs 600 crore (40% YoY) and ePharmacy hit breakeven. Offline footprint to scale from 280 to 500+ stores within 12 months under an omnichannel push, with D2C at Rs 200 crore ARR and Speciality Pharma growing 65%.
Tata 1mg turned EBITDA positive across core businesses in FY26, with diagnostics crossing Rs 600 crore ARR and ePharmacy hitting breakeven. The company plans to expand offline retail from 280 to 500+ stores within 12 months under an omnichannel strategy.
Why this matters
Tata 1mg crosses profitability milestone as diagnostics scales past Rs 600 cr ARR and ePharmacy hits breakeven, signaling maturation of its omnichannel healthtech model alongside aggressive offline expansion.
Retail-company signals steady at 1292 in last 90 days.